A local company knows how to get it into the right hands
In late June, two pharmaceutical companies formalized an eighth collaboration that quietly expands the architecture of cancer care across mainland China. Innovent Biologics, a Suzhou-based firm with fifteen years of distribution experience, will now hold exclusive commercialization rights for Verzenios — Eli Lilly's CDK4&6 inhibitor already proven effective across multiple breast cancer indications. The agreement reflects something larger than a business transaction: it signals that Chinese pharmaceutical infrastructure has matured to the point where a domestic company can be entrusted with bringing a globally significant oncology drug to the patients who need it most.
- Breast cancer incidence among Chinese women has been rising for years, and access to effective treatment remains uneven across the country's vast geography.
- Verzenios had already cleared a critical barrier — becoming the first drug in its class covered by China's national reimbursement program in 2021, with that coverage renewed in 2025 — but distribution remained a bottleneck.
- Innovent's established oncology network, built across hospitals, regulatory pathways, and provincial markets, now becomes the engine for getting this drug into patients' hands.
- Lilly retains manufacturing and development responsibilities, creating a division of labor that plays to each company's deepest strengths.
- With Verzenios added, Innovent's portfolio reaches nineteen on-market products, cementing its position as a serious force in China's oncology commercialization landscape.
On a Monday in late June, Innovent Biologics and Eli Lilly announced their eighth collaboration — this time granting Innovent exclusive rights to market, import, and distribute Verzenios across mainland China. The drug, which works by blocking CDK4 and CDK6 proteins that cancer cells rely on to grow, is approved for several breast cancer indications, including early-stage tumors at high risk of recurrence and advanced cases paired with various endocrine therapies.
Verzenios had already achieved something significant before this deal: in 2021 it became the first drug in its class covered under China's National Reimbursement Drug List, making it genuinely affordable for ordinary patients. That coverage was renewed in full in 2025. What the new agreement adds is a commercialization engine — Innovent's deep network of hospital relationships, regulatory expertise, and provincial distribution channels built over fifteen years.
Innovent's founder Michael Yu framed the deal as a natural deepening of a partnership that had already produced seven marketed products in China. Lilly's China general manager Huzur Devletsah described it as a marriage of strengths: 150 years of Lilly research and development paired with Innovent's intimate knowledge of how medicines move through China's healthcare system. Lilly had already had a strong year in Chinese oncology, including the approval of Inluriyo, the first precision therapy targeting the ESR1 genetic mutation in advanced breast cancer.
Breast cancer remains one of the most common and deadly cancers among Chinese women, with incidence climbing in recent years. The combination of national reimbursement coverage and Innovent's distribution reach means the drug can now arrive in cities and provinces where it might previously have been inaccessible or unaffordable. For many patients, that difference is measured not in market share, but in time.
On a Monday in late June, two pharmaceutical companies announced they had struck a deal that would reshape how one breast cancer drug reaches patients across mainland China. Innovent Biologics, a Suzhou-based firm that has spent fifteen years building a distribution network across the country, would now handle all the marketing, importing, and selling of Verzenios—a drug made by Eli Lilly that blocks two proteins known as CDK4 and CDK6, which cancer cells often depend on to grow.
Verzenios had already been approved in China for several forms of breast cancer. It could be used alongside hormone therapy to treat early-stage tumors in women at high risk of recurrence. It worked in advanced cases too, paired with different endocrine drugs depending on what the patient had already tried. And in 2025, just months before this announcement, it had achieved something significant: full coverage under China's National Reimbursement Drug List, the government program that determines which medicines ordinary patients can actually afford. This mattered because Verzenios had been the first drug in its class to win that coverage at all, back in 2021.
The partnership itself was the eighth between these two companies. Innovent's founder and chief executive, Michael Yu, framed it as deepening a relationship that had already produced seven marketed products in China. With Verzenios, Innovent's portfolio would reach nineteen drugs. The company had built its reputation on oncology—cancer treatment—and breast cancer was now a strategic focus. Lilly, for its part, would keep doing what it does best: manufacturing the drug, supplying it, and continuing to develop it further. Innovent would own the commercialization rights, meaning it would decide how to market the drug, where to distribute it, and how to work with hospitals and doctors to get it into patients' hands.
Huzur Devletsah, Lilly's China general manager, described the arrangement as a marriage of strengths. Lilly brought 150 years of research and development expertise. Innovent brought deep knowledge of how to sell medicines in China—the relationships, the regulatory pathways, the understanding of what doctors and patients needed. He noted that Lilly had already had a strong year in China's oncology space, winning approvals for new medicines and new uses for existing ones. Inluriyo, another Lilly drug, had just become the first precision therapy approved in China specifically for a genetic mutation called ESR1 in advanced breast cancer.
Breast cancer remains one of the most common and deadly cancers among Chinese women. The disease had been climbing in incidence for years, driven partly by aging populations and changing risk factors. Access to effective treatment had improved but remained uneven across the country. A drug like Verzenios, now covered by national reimbursement and distributed through Innovent's established channels, could reach patients in cities and provinces where it might otherwise have been out of reach or prohibitively expensive.
Innovent itself had grown into something substantial. Founded in 2011, it now employed thousands and maintained partnerships with more than thirty global pharmaceutical companies—Takeda, Pfizer, Roche, Sanofi, and others alongside Lilly. The company had one drug in regulatory review, five in late-stage clinical trials, and fourteen more in earlier development. It had built manufacturing capacity and quality standards that allowed it to produce biopharmaceuticals—complex drugs made from living cells—at scale.
What made this deal worth announcing was not the novelty of the arrangement itself. Pharmaceutical companies partner constantly. What mattered was the signal it sent: that a Chinese company had become trusted enough to hold exclusive commercialization rights for an important cancer drug from one of the world's largest pharmaceutical makers. It suggested that the infrastructure for getting innovative medicines to Chinese patients had matured. And it meant that women with breast cancer in mainland China would have one more pathway to a treatment that, for many, could extend life or improve its quality.
Notable Quotes
Enhancing patient access to high-quality, innovative medicines has always been at the core of Innovent's mission.— Michael Yu, Founder, Chairman and CEO of Innovent Biologics
This agreement combines Lilly's global R&D expertise with Innovent's commercialization capabilities in China.— Huzur Devletsah, Lilly Group Vice President and China General Manager
The Hearth Conversation Another angle on the story
Why does it matter that Innovent gets the distribution rights rather than Lilly handling it directly?
Lilly is global, but Innovent knows China—the hospitals, the doctors, the reimbursement system, the way information flows. A foreign company can make the drug, but a local company knows how to get it into the right hands.
So this is really about access?
Partly. But it's also about trust. Lilly is saying, "We believe Innovent can sell this better than we can." That's a vote of confidence in a Chinese company.
The drug was already approved in China. What changes now?
Approval is one thing. Getting it to patients is another. Innovent has the relationships with hospitals, the sales force, the knowledge of which doctors treat which patients. They can make sure the drug actually reaches people who need it.
Why is the reimbursement coverage so important?
Without it, the drug costs too much for most patients. With it, the government pays part of the cost. That's the difference between a drug that exists in theory and one that actually gets prescribed.
Is this a sign that Chinese companies are becoming more important in global pharma?
It's a sign that some Chinese companies have become sophisticated enough to handle the whole business of getting a medicine to market—not just manufacturing it, but understanding patients, doctors, regulators, and how to navigate all of that. That's a real shift.